Podcasts about wet amd

Eye specialists say some Kiwis are at risk of going blind, because they're not getting access to the care they need to treat one of the most common causes of vision loss.

Time flies: Some wet AMD patients have had the Port Delivery System with Ranibizumab (Susvimo, Genentech/Roche) for more than 5 years. How well does vision hold up at 5 years? And how do those numbers compare to 5-year endpoints in injection-based studies? John Kitchens, MD, reviews the dynamics around the PORTAL study, which assessed outcomes after 5 years of PDS treatment. And Krishna Mukkamala, MD, reviews data from a first-ever study validating longitudinal performance of AI-based home OCT (Scanly Home OCT, Notal Vision) compared with human experts. Just how sensitive and specific was home OCT compared with human graders? 

Susvimo is an FDA-approved treatment that continuously delivers drug through a tiny, implanted capsule

What do you do when a patient with GA also has wet AMD? And how do you encourage patients on anti-complement therapy to stick with treatment? In part 2 of this 2-part series, moderator Judy Kim, MD, and panelists Rishi Singh, MD; Deepak Sambhara, MD, and Sunir Garg, MD, examine answers to these questions. 

Could addressing fibrosis in wet AMD and DME unlock greater durability of treatment? Marion Munk, MD, PhD, joins the show to discuss results from the phase 2a BETTER study, which assessed the use of the anti-fibrosis agent ISTH0036 in patients with wet AMD and DME. And Diana Do, MD, sits down to review data from the LIGHTSITE IIIB study, which examined whether patients who underwent photobiomodulation therapy realized any benefit after re-administration following a 13-month washout period. Did the break in treatment lead to irreversible vision loss? Or were patients able experience a benefit after taking more than a year off? We have the answers in this episode. 

In earlier clinical trials, the emerging gene therapy greatly reduced the treatment burden associated with injections of approved anti-VEGF therapies.

Join us for an in-depth discussion on the latest developments in wet age-related macular degeneration treatment. We're partnering with the American Society of Retina Specialists (ASRS) to bring you an overview of current treatment options, the impact of the Avastin shortage, and alternative treatments. We will also explore advocacy efforts by ASRS and the American Academy of Ophthalmology to address these issues.

Does switching wet AMD patients from aflibercept (Eylea, Regeneron) to faricimab (Vabysmo, Genentech) improve disease outcomes? Join Ben Young, MD, MS, and his guests Lediana Goduni, MD, and Joshua Uhr, MD, as they explore this a recent peer review paper on this question. What are the potential benefits of such a switch? How should providers use findings such as these to inform their practice? And are significant improvements in anatomy relevant if vision gains are unchanged? 

The ELEVATUM study exclusively enrolled historically underrepresented patients in a study assessing faricimab (Vabysmo, Genentech/Roche) for DME. Were there any surprises in the data? Jeremiah Brown, MD, MS, sits down with New Retina Radio to review the philosophy behind the ELEVATUM study, discuss the study's findings, and preview the next phases of the trial. And Eric Schneider, MD, joins the program to discuss the findings of a pivotal study assessing home OCT (Scanly, Notal Vision) in wet AMD patients. Is home OCT equivalent to in-office OCT when it comes to visualization? And do expert graders agree with an AI algorithm's assessments of patient's pathology?

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Dennis O. Clegg, Ph.D., discusses treatments for age-related macular degeneration (AMD), a condition that causes vision loss. Clegg explains that while patients often report improved vision after receiving implants, objective tests don't always confirm this. He explores the potential differences in patients' responses based on genetics and disease progression. There is also an ongoing challenge in finding the best ways to reduce immune rejection of these treatments. New trials are underway to test implants in earlier stages of the disease, and researchers are looking at different strategies like localized immunosuppression. Additionally, some studies suggest that secretions from retinal cells may help preserve vision. Overall, there are many open questions, but advances in the field offer hope for better AMD treatments. Series: "Stem Cell Channel" [Health and Medicine] [Science] [Show ID: 39459]

Tens of thousands of real-world geographic atrophy patients were analyzed in a retrospective database study. How did GA progress—and how do these data inform our understanding of GA? Ted Leng, MD, stopped by the show to share the findings from his research on the natural history of GA, which he recently delivered on the podium in Lisbon. And Michael Klufas, MD, joined us for a discussion about another real-world study. This time, it was a retrospective multicenter outcomes analysis following multiple injections of high-dose aflibercept (Eylea HD, Regeneron) for treatment of wet AMD, DME, and DR. How did treatment-naïve patients fare compared with previously treated patients? And did treatment intervals improve? Stick with us to find out.

Known as 4D-150, the wet AMD gene therapy performed well in a Phase 2b clinical trial.

Does switching long-term wet AMD patients to faricimab (Vabysmo, Genentech/Roche) result in meaningful change to disease presentation? Join New Retina Radio Journal Club host Ben Young, MD, MS, and panelists Lediana Goduni, MD, and Josh Uhr, MD, as they break down a recent real-world study published in the literature. After the break, they review whether the study's findings could inform clinical decision-making, weigh the value of anatomic improvement that doesn't result in significant improvement in vision quality, and review their comfort with switching from legacy anti-VEGF agents to next-generation therapies.

New steroid-free topical for atopic dermatitis; A refillable ocular implant for the treatment of  neovascular (wet) age-related macular degeneration returns following recall; A neuroimmune modulation device shows clinical benefit in adults with rheumatoid arthritis; FDA denies Novo Nordisk's once-weekly insulin icodec; And a smarthphone therapy shows benefit for patients with fibromyalgia.

FDA-approved in 2021, the tiny implantable capsule provides sustained delivery of treatment, but was recalled in 2022.

Alice Findlay, RNIB Customer Voice Insight Co-ordinator shares the latest opportunities for blind and partially sighted people to get involved in with RNIB Connect Radio's Toby Davey. Opportunities highlighted this week included: Parenting with a Vision Impairment In-Person Discussion Join us for an in-person discussion on parenting with a vision impairment, hosted by RNIB's Stories and CYPF teams as part of Spotlight on Stories week. The event takes place on 20 June from 11am-1.30pm at RNIB's London office - the Grimaldi building, 154a Pentonville Road, London, N1 9JE on the third-floor mezzanine. CYPF Family Support Officer and former ECLO Jenny Molineux will share her experiences as a visually impaired mum and introduce the CYPF Parenting with Vision Impairment guide. She will be joined by other mothers with vision impairments to discuss their challenges, followed by a Q&A session. Sensitive topics will be covered. There's limited capacity for the event, so please RSVP to stories.library@rnib.org.uk by Friday 14 June if you'd like to attend.  Do you have Geographic Atrophy (GA) or care for someone who does?  Take part in a study and earn £65! Geographic Atrophy (also known as GA) is most often seen in people who live with Wet AMD, Dry AMD, Glaucoma and Cataracts. Exafield UK (a medical market research company) are carrying out research on behalf of a pharmaceutical company. The aim of their research is to understand your journey with GA. By collecting these experiences, they hope to build a better picture of eyesight degeneration and understand what could be improved to better manage this condition. The study will consist of a 30-minute pre-task homework completed online and a 75-minute online interview. As a thank you for your time, you will receive £65, which is payable as a bank transfer, Cheque or Amazon Voucher. If you're interested in taking part in the study, please send an email to involvement@rnib.org.uk and we will send you the link to apply to take part in the study.  Are you living with sight loss and are interested in sharing your experiences of relationships and sexual well-being?  SASH, a mental health and wellbeing charity focused on sexual health who offer a range of services including counselling, coaching, peer support, training, and workshops. They are looking for people who would be willing to be interviewed and recorded as part of their podcast series on sexual health. If this interests you, they would love to interview you to help raise awareness, discuss barriers you experience, and address misconceptions around relationships for those navigating life with sight loss.  Complimentary drinks, snacks and a £50 Amazon voucher will be provided as a thank you for sharing your lived experience with SASH. To get involved contact Sade Vassel either by phone on 07928 512 465 or email sade.vassel@turning-point.co.uk. To find out more about these and other Connect Voices opportunities along with how you can get involved with RNIB Connect Voices do visit- https://www.rnib.org.uk/connect-community/connect-voices-network/connect-voices-current-opportunities (Image shows RNIB logo. 'RNIB' written in black capital letters over a white background and underlined with a bold pink line, with the words 'See differently' underneath)

Dr. Sarraf talks about his group's work on the correlation of PED size and variablity and the visual improvement during the treatment of neovascular AMD as analyzed using data from HAWK and HARRIER studies. Referenced article:  Sarraf D, Khanani AM, Sadda SR, Chang A, Wong DT, Kempf AS, Saffar I, Tang S, Tadayoni R. PIGMENT EPITHELIAL DETACHMENT THICKNESS AND VARIABILITY AFFECTS VISUAL OUTCOMES IN PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION. Retina. 2024 Jan 1;44(1):10-19. doi: 10.1097/IAE.0000000000003935. PMID: 37824807.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPZ865. CME credit will be available until December 21, 2024.Optimizing Real-World Outcomes in Wet AMD: Reducing the Burden of Treatment With Longer-Acting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRishi P. Singh, MD, FASRS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Apellis Pharmaceuticals; Bausch & Lomb Incorporated; Genentech, Inc.; IVERIC bio, Inc., An Astellas Company; Novartis/Gyroscope; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME information, and to apply for credit, please visit us at PeerView.com/BPZ865. CME credit will be available until December 21, 2024.Optimizing Real-World Outcomes in Wet AMD: Reducing the Burden of Treatment With Longer-Acting Therapies In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerRishi P. Singh, MD, FASRS, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Alcon; Apellis Pharmaceuticals; Bausch & Lomb Incorporated; Genentech, Inc.; IVERIC bio, Inc., An Astellas Company; Novartis/Gyroscope; and Regeneron Pharmaceuticals Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

What are the consequences to intentional suspension of anti-VEGF therapy in wet AMD patients? Join moderator Sruthi Arepalli, MD, and panelists Rebecca Soares, MD, MPH, and Vaidehi Dedania, MD, as they explore the circumstances under which treatment might be suspended, examine a paper that described the consequences of treatment suspension, and review how they approach treatment suspension in their clinics.

They're here: the 96-week data on aflibercept 8 mg (Eylea, Regeneron) in wet AMD. Jean-Francois Korobelnik, MD, PhD stops by to review the 96-week data from PULSAR. How closely did the 96-week results match those at 48 weeks? And how many patients could be extended to 16-, 20-, or even 24-week intervals?    Also, W. Lloyd Clark, MD, joins the show to discuss home-based OCT-guided management of wet AMD. How does home OCT fit into a patient's life—and how might it shape the future of care? Listen here to find out. 

Guest speaker W. Lloyd Clark, MD, discusses a new anti-VEGF treatment option that is available for wet AMD. Dr. Clark specializes in the treatment of vitreous and retinal diseases. He is also dedicated to the advancement of new treatments for retinal diseases through his involvement with clinical trials for the newest therapies for age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions.

Drs. Katherine Talcott and Joshua Uhr preview the September 2023 issue of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include high-dose aflibercept FDA approval, management of treatment-resistant wet AMD patients, biosimilar intravitreal injections, and lifestyle factors and AMDRelevant Financial Disclosures: Dr. Sridhar is a consultant for Genentech and Regeneron. Dr. Talcott is a consultant for Genentech.You can claim CME credits for prior episodes via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

In this episode, Ayesha talked about how three more US states have filed a lawsuit against Eli Lilly over its proposed $13.5 million insulin pricing settlement. The states join six others who have been fighting Eli Lilly in court since 2017, claiming that the company hiked prices of its insulin product Humalog. The states say the $13.5 million settlement offer from Eli Lilly doesn't come close to the $1 billion worth of claims the company is facing. Hear more about the insulin pricing controversy in this episode.Ayesha also talked about the FDA approval of Regeneron's high dose Eylea (HD Eylea) for the treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR). Hear about how high dose Eylea offers less frequent dosing regiments, and how it will be facing Roche's blockbuster eye injection Vabysmo.Read the full articles here:More US States Take on Eli Lilly in Court Over Proposed $13.5 Million Insulin Pricing SettlementRegeneron's High Dose Eylea Gets FDA Nod for Wet AMD and DMEFor more life science and medical device content, visit the Xtalks Vitals homepage.Follow Us on Social MediaTwitter: @Xtalks Instagram: @Xtalks Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured

New Retina Radio was at ASRS 2023 to cover the stories you may have missed.    How often do patients return to the clinic on time for anti-VEGF injections? Christina Y. Weng, MD, MBA, and her team explored how often patients missed scheduled appointments, by how much, and whether missing appointments affected patient outcomes.    And Nikolas JS London, MD, joined us in our mobile studio in Seattle to tell us about anatomic outcomes in wet AMD patients after faricimab (Vabysmo, Genentech/Roche) treatment.    This is episode 1 of 2 covering the 2023 ASRS Annual Meeting. Keep an eye on your feed for episode 2.  

Were fluid-free visits correlated with outcomes in the HAWK/HARRIER studies? Moderator Katherine Talcott, MD, and panelists Kyle Kovacs, MD, and Rebecca Soares, MD, MPH, summarize data from a study examining this question, review what it means to be "free of fluid," and discuss how these data fit into the overall conversation about fluid toleration in wet AMD. 

How are doctors using faricimab (Vabysmo, Genentech/Roche) in real-world settings? The IRIS Registry has a few answers. We sat down with Durga Borkar, MD, MMCi, to hear what researchers in the FARETINA-AMD study group found regarding dynamics related to faricimab's use in wet AMD patients since its approval in January of last year.    We also interviewed Varun Chaudhary, MD, to learn specifically about faricimab treat-and-extend regimens in wet AMD patients who were enrolled in TENAYA and LUCERNE. How many patients achieved treatment intervals of 12 or 16 weeks? 

This event featured Dr. Surendra Sharma, Senior VP of Medical Affairs at Outlook Therapeutics. Dr. Sharma discussed the difference between Wet AMD and Dry AMD, who is at risk for Wet AMD, and what treatment options are available.

Dr. Jay Duker speaks about the results of the DAVIO trial which was a phase 1 trial investigating an intravitreal implant (EYP-1901) containg vorolanib (a VEGF and receptor blocker) in a bioerodible Durasert implant for the treatment of wet AMD. 

Millions of people in the United States live with eye conditions that can cause blindness if left untreated. One of the most common causes of vision loss later in life is age-related macular degeneration and wet AMD, an advanced form that can cause severe and rapid vision loss, but it can be stopped or slowed if caught early enough. Dr. Talia Kaden, is an ophthalmologist at Manhattan Eye, Ear and Throat Hospital joins me ways to help you prioritize your eye health and about treatments for wet AMD.

Millions of people in the United States live with eye conditions that can cause blindness if left untreated. One of the most common causes of vision loss later in life is age-related macular degeneration and wet AMD, an advanced form that can cause severe and rapid vision loss, but it can be stopped or slowed if caught early enough. Dr. Talia Kaden, is an ophthalmologist at Manhattan Eye, Ear and Throat Hospital joins me ways to help you prioritize your eye health and about treatments for wet AMD.This show is part of the Spreaker Prime Network, if you are interested in advertising on this podcast, contact us at https://www.spreaker.com/show/3501571/advertisement

Max Conway, RNIB's National Involvement Coordinator, shares the latest opportunities for blind and partially sighted people to get involved in. Opportunities highlighted this week included: Call out for would-be blind or partially sighted movie stars to be part of a short film about Wet-AMD. Fixing US, a health engagement organisation focusing on patient journeys across all kinds of health conditions are looking for people living with Wet-AMD who would be willing to participate in a short film about their condition. Do you play a musical instrument and would like to break down the barriers blind and partially sighted musicians face? Rachel, a PhD student at the University of Plymouth, is looking to gather information from blind and partially sighted musicians to help aid the development of an accessible digital musical interface that will enable visually impaired musicians to play in an ensemble setting alongside sighted musicians.   To find out more about these items and how you can get involved with RNIB Connect Voices do visit - https://www.rnib.org.uk/connect-community/connect-voices-network/connect-voices-current-opportunities (Image shows RNIB logo. 'RNIB' written in black capital letters over a white background and underlined with a bold pink line, with the words 'See differently' underneath) 

Drs. Marcus and Singer explore the topic individualizing the treatment approach in Wet AMD including treat and extend, monthly or maximum tolerated interval. Dr. Singer goes into depth on his approach to “treat and extend” including certain caveats and circumstances that could change how long he would extend a patient as well as the importance of balancing convenience, adherence, and efficacy.

BrightFocus Foundation held this Access Live Event to speak with participants about eye care. Our guest speaker was Alicia Menezes, M.D., a Medical Director in U.S. Medical Affairs, Ophthalmology at Genentech. Topics of discussion included comprehensive exams, treatments, and new advances in research.

Charlotte Jones, RNIB's National Involvement Coordinator shares the latest opportunities for blind and partially sighted people to get involved in. Opportunities highlighted this week included: Did you have a power cut for 2 or more days because of a winter storm? A team from Kings College London are looking for people with a disability or health  condition who experienced power cuts for 2 days or more during the 2021–22 winter season to share their experiences with researchers in a video or telephone call to find out what support people need in future power cuts. Join a virtual forum and share your experiences of Wet-AMD to help raise awareness! Fixing Dad, a health engagement organisation who look into patient journeys across all kinds of health conditions are looking for people living with wet-AMD who would be willing to participate in a one-hour online discussion to share their experiences about what it's like for them to live with Wet-AMD. The RNIB website is being redeveloped and we need your help! Our website rnib.org.uk is in the process of being updated and redeveloped and we need your help with user testing. Earlier this year we held interviews with different types of users to understand their experiences of our website and now, we're asking for help to test the prototypes of our new website. We are keen to hear from the friends and family of blind and partially sighted people and also people who have been recently diagnosed with sight loss.  To find out more about these items and how you can get involved with RNIB Connect Voices do visit - https://www.rnib.org.uk/connect-community/connect-voices-network/connect-voices-current-opportunities (Image shows RNIB logo. 'RNIB' written in black capital letters over a white background and underlined with a bold pink line, with the words 'See differently' underneath) 

Drs. Shriji Patel, Safa Rahmani, and Marianeli Rodriguez join to discuss the April 2022 edition of Retinal Physician, found online at http://www.retinalphysician.com. Topics covered include photobiomodulation for retinal disease, strategies for dry and wet macular degeneration, and more.Relevant Financial Disclosures: Dr. Sridhar is a consultant for Genentech and Regeneron. Drs. Patel, Rahmani, and Rodriguez have no relevant disclosures. You can now claim CME credits via the AAO website. Visit https://www.aao.org/browse-multimedia?filter=Audi

Have innovations in therapy actually led to a paradigm shift when it comes to encountering patients with newly diagnosed wet AMD? In the season finale of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by panelists Lejla Vajzovic, MD, and Joseph M. Coney, MD, to review strategies for treating new wet AMD patients, to discuss where new technologies fit into a treatment algorithm, and to examine the best time to switch patients to a new therapeutic option. After the break, Dr. Khanani updates the panel on a patient case shared in previous seasons of this series, which involves a patient with a 12-year treatment history who experienced significant vision loss following a change in therapy. How did Dr. Khanani manage the case—and what happened after inflammation was brought under control?   This editorially independent podcast is supported with advertising.

Kodiac Sciences is developing KSI-301 for a number of proliferative endothelial retinal disorders. Their recent P3 wet AMD data readout failed to show non-inferiority to Q8W dosed Eylea, a major upset for the company. However, KOD has a number of other upcoming P3 trial readouts that will be massive movers for the stock. In this episode, I go over the P3 data and talk about whether or not this is a buying opportunity. I also talk about Karyopharm and their recent regulatory update about the SIENDO data. Thanks to InfoPathways for being a sponsor of the show! Check them out for all your biotech IT needs at infopathways.com or call 410-751-9929. Help out the show (or join the discord) by becoming a patron at: https://www.patreon.com/breakingbiotech Follow me on twitter @matthewlepoire Send me an email matthewlepoire@gmail.com www.breakingbiotech.com #breakingbiotech Disclaimer: All opinions expressed by Matt (or his guests) in this podcast are solely his (their) opinions. You should not treat any opinion expressed by Matt in this podcast as a specific inducement to make a particular investment or follow a particular strategy, but only as an expression of his opinion. Matt's opinions are based upon information he considers reliable, but Matt (nor his guests) cannot warrant its completeness or accuracy, and it should not be relied upon as such. Matt (nor his guests) is/are not under any obligation to update or correct any information provided in this podcast. Past performance is not indicative of future results. Matt (nor his guests) does/do not guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed in this podcast. #biotech

How have the most recent advances in wet AMD therapy changed the treatment landscape for clinicians? In this debut episode of the third season of “The Art of Drug Choice,” moderator Arshad M. Khanani, MD, MA, is joined by Lejla Vajzovic, MD, and Joseph M. Coney, MD, for a discussion about choosing patients who are best suited for the recently approved therapies, and for a preview of how biosimilars could affect treatment decisions. After the break, Dr. Coney shares the case of a patient whose need to extend treatment intervals was addressed by switching to a new anti-VEGF agent. This editorially independent podcast is supported with advertising.

Peter Kaiser, MD and Carol Regillo, MD, FACS discuss the port delivery system and how it impacts treatment of wet AMD.

The US Food & Drug Administration (FDA) has approved Susvimo, Genentech's port delivery system (PDS) with ranibizumab, for the treatment of wet age-related macular degeneration (AMD). The PDS, a refillable capsule the size of a rice grain, provides continual release of ranibizumab, a protein that blocks the growth of vision-robbing, leaky blood vessels which are the hallmark of wet AMD. The PDS is implanted at the surface of the eye during a one-time, outpatient, surgical procedure. The PDS may be refilled as infrequently as twice a year. Susvimo will be available to patients in the coming months.

Dr. Carmen Puliafito interviews Andrew Moshfeghi, MD on a topic: Tyrosine Kinase Inhibitor Delivery by Hydrogel for Treatment of Wet AMD

Dr. Dugel discusses 1 and 2 year results of HAWK and HARRIER on Brolucizumab for neovascular AMD.  Full reference:  Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., . . . Investigators, H. S. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2019.04.017  

Dr. Mark Gillies from Sydney, Australia discusses 2-year results of the RIVAL Study which investigated rates of geographic atrophy and visual acuity changes in patients with wet AMD.   Full reference:  Gillies, M. C., Hunyor, A. P., Arnold, J. J., Guymer, R. H., Wolf, S., Ng, P., . . . McAllister, I. L. (2019). Effect of Ranibizumab and Aflibercept on Best-Corrected Visual Acuity in Treat-and-Extend for Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. doi:10.1001/jamaophthalmol.2018.6776